Biosimilars Take The Stage As Regulatory Debate Goes Global (Part 2 of 2)
This article was originally published in PharmAsia News
With more emerging economies starting to look to biosimilars as a potential source of cost savings on expensive biological medicines, discussions are intensifying over issues such as the regulatory systems used to approve biosimilars, how best to monitor their safety, and what names they should carry.
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.